Damora Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$210.9M | -$22.3M | -$39.9M | -$61.2M | -$52.2M |
| Operating expenses | $210.9M | $22.3M | $39.9M | $61.2M | $52.2M |
| Cash from operations | -$6.7M | -$18.6M | -$36.9M | -$42.9M | -$52.3M |
| Capital expenditure | — | — | — | $196,000 | $223,000 |
| Free cash flow | — | — | — | -$43.1M | -$52.5M |
| Total assets | $260.5M | $17.1M | $38.2M | $73.2M | $122.2M |
| Total liabilities | $20.1M | $1.3M | $5.9M | $11.4M | $5.0M |
Shares outstanding 61.6M · Free float 97.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.